Shares of GlaxoSmithKline Pharmaceuticals were trading higher in Thursday's session, with the stock marked at Rs 2,879.10, a 3.68% increase. At 10:55 am, the stock is among the top gainers on the Nifty Midcap 150 index.
GlaxoSmithKline Pharmaceuticals announced several press releases on August 25, 2025, regarding the company's foray into oncology with Jemperli and Zejula, bringing precision therapies for gynaecological cancers.
GlaxoSmithKline Pharmaceuticals has announced a final dividend of Rs 42 per share with effective date as May 30, 2025.
Financial Performance:
The following table summarizes the consolidated quarterly financial performance of GlaxoSmithKline Pharmaceuticals:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 814.65 Crore | Rs 1,010.77 Crore | Rs 949.42 Crore | Rs 974.37 Crore | Rs 805.17 Crore |
| Net Profit | Rs 182.33 Crore | Rs 252.50 Crore | Rs 229.88 Crore | Rs 262.87 Crore | Rs 205.01 Crore |
| EPS | 10.76 | 14.91 | 13.57 | 15.52 | 12.10 |
The following table summarizes the consolidated yearly financial performance of GlaxoSmithKline Pharmaceuticals:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,925.60 Crore | Rs 3,278.03 Crore | Rs 3,251.72 Crore | Rs 3,453.71 Crore | Rs 3,749.21 Crore |
| Net Profit | Rs 287.27 Crore | Rs 380.77 Crore | Rs 607.64 Crore | Rs 589.96 Crore | Rs 927.58 Crore |
| EPS | 31.35 | 99.29 | 36.08 | 41.14 | 54.52 |
| BVPS | 87.26 | 157.19 | 102.79 | 104.93 | 115.19 |
| ROE | 24.22 | 63.64 | 35.41 | 33.42 | 47.67 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Consolidated yearly income statement:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | 3,749 | 3,453 | 3,251 | 3,278 | 2,925 |
| Other Income | 145 | 122 | 100 | 75 | 110 |
| Total Income | 3,895 | 3,576 | 3,352 | 3,353 | 3,036 |
| Total Expenditure | 2,633 | 2,758 | 2,514 | 2,572 | 2,578 |
| EBIT | 1,261 | 817 | 838 | 781 | 457 |
| Interest | 1 | 1 | 1 | 2 | 3 |
| Tax | 332 | 226 | 228 | 398 | 166 |
| Net Profit | 927 | 589 | 607 | 380 | 287 |
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | 805 | 974 | 949 | 1,010 | 814 |
| Other Income | 43 | 40 | 35 | 34 | 35 |
| Total Income | 848 | 1,015 | 984 | 1,045 | 850 |
| Total Expenditure | 569 | 655 | 676 | 701 | 600 |
| EBIT | 279 | 359 | 308 | 344 | 249 |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Tax | 73 | 95 | 78 | 91 | 67 |
| Net Profit | 205 | 262 | 229 | 252 | 182 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | 1,289 | 582 | 484 | 810 | 577 |
| Investing Activities | -45 | 8 | 807 | -405 | 418 |
| Financing Activities | -769 | -561 | -1,543 | -524 | -696 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 474 | 29 | -251 | -119 | 300 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | 169 | 169 | 169 | 169 | 169 |
| Reserves & Surplus | 1,781 | 1,617 | 1,573 | 2,493 | 1,308 |
| Current Liabilities | 1,905 | 1,524 | 1,326 | 1,698 | 1,354 |
| Other Liabilities | 251 | 245 | 257 | 271 | 281 |
| Total Liabilities | 4,108 | 3,556 | 3,326 | 4,633 | 3,114 |
| Fixed Assets | 297 | 335 | 350 | 361 | 400 |
| Current Assets | 3,409 | 2,798 | 2,494 | 3,708 | 2,202 |
| Other Assets | 400 | 423 | 482 | 564 | 511 |
| Total Assets | 4,108 | 3,556 | 3,326 | 4,633 | 3,114 |
| Contingent Liabilities | 490 | 387 | 361 | 368 | 498 |
| Ratio | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 31.35 | 99.29 | 36.08 | 41.14 | 54.52 |
| Diluted Eps (Rs.) | 21.14 | 100.04 | 36.05 | 34.83 | 54.76 |
| Book Value /Share (Rs.) | 87.26 | 157.19 | 102.79 | 104.93 | 115.19 |
| Dividend/Share (Rs.) | 30.00 | 90.00 | 32.00 | 32.00 | 54.00 |
| Face Value | 10 | 10 | 10 | 10 | 10 |
| Gross Profit Margin (%) | 24.22 | 25.55 | 27.82 | 29.86 | 35.29 |
| Operating Margin (%) | 21.53 | 23.47 | 25.80 | 27.84 | 33.51 |
| Net Profit Margin (%) | 12.24 | 51.69 | 18.78 | 17.08 | 24.74 |
| Return on Networth (%) | 24.22 | 63.64 | 35.41 | 33.42 | 47.67 |
| ROCE (%) | 35.80 | 26.21 | 41.95 | 47.33 | 57.03 |
| Return On Assets (%) | 11.49 | 36.57 | 18.53 | 16.70 | 22.64 |
| Current Ratio (X) | 1.63 | 2.18 | 1.88 | 1.84 | 1.79 |
| Quick Ratio (X) | 1.22 | 1.87 | 1.53 | 1.49 | 1.54 |
| Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratios (X) | 200.69 | 419.65 | 499.36 | 573.35 | 1,007.30 |
| Asset Turnover Ratio (%) | 0.94 | 0.83 | 0.81 | 1.00 | 0.98 |
| Inventory Turnover Ratio (X) | 0.90 | 1.04 | 0.81 | 1.11 | 0.99 |
| 3 Yr CAGR Sales (%) | 0.94 | 2.37 | 0.42 | 8.65 | 6.95 |
| 3 Yr CAGR Net Profit (%) | -9.50 | -7.54 | 155.34 | 43.31 | 56.08 |
| P/E (x) | 45.96 | 16.79 | 36.72 | 47.32 | 52.83 |
| P/B (x) | 16.51 | 10.58 | 12.88 | 18.52 | 24.98 |
| EV/EBITDA (x) | 32.80 | 30.67 | 23.51 | 30.89 | 35.77 |
| P/S (x) | 8.34 | 8.59 | 6.90 | 9.53 | 13.00 |
With the stock currently priced at Rs 2,879.10, GlaxoSmithKline Pharmaceuticals has seen a gain of 3.68% in today's session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
